While recently developed small-molecule inhibitors have a role in subsets of AML (e.g., IDH1/2 and FLT3 mutated) [20], because of the genetic heterogeneity of this disease they are unlikely to be broadly applicable. The gene discussed is FLT3; the disease is acute myeloid leukemia.